skip to content

Kyle, Margaret K.

Overview
Works: 10 works in 42 publications in 1 language and 211 library holdings
Classifications: HB1, 332
Publication Timeline
Key
Publications about Margaret K Kyle
Publications by Margaret K Kyle
Most widely held works by Margaret K Kyle
Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? by Allen N Berger( Book )
15 editions published between 2000 and 2001 in English and held by 93 libraries worldwide
We test three hypotheses regarding changes in supervisory toughness' and their effects on bank lending. The data provide modest support for all three hypotheses that there was an increase in toughness during the credit crunch period (1989-1992), that there was a decline in toughness during the boom period (1993-1998), and that changes in toughness, if they occurred, affected bank lending. However, all of the measured effects are small, with 1% or less of loans receiving harsher or easier classification, about 3% of banks receiving better or worse CAMEL ratings, and bank lending being changed by 1% or less of assets
Investments in pharmaceuticals before and after TRIPS by Margaret K Kyle( Computer File )
9 editions published between 2009 and 2011 in English and held by 48 libraries worldwide
We examine the relationship between patent protection for pharmaceuticals and investment in development of new drugs. Patent protection has increased around the world as a consequence of the TRIPS Agreement, which specifies minimum levels of intellectual property protection for members of the World Trade Organization. It is generally argued that patents are critical for pharmaceutical research efforts, and so greater patent protection in developing and least-developed countries might result in greater effort by pharmaceutical firms to develop drugs that are especially needed in those countries. Since patents also have the potential to reduce access to treatments through higher prices, it is imperative to assess whether the benefits of increased incentives have materialized in research on diseases that particularly affect the poor. We find that patent protection is associated with increases in research and development (R & D) effort when adopted in high income countries. However, the introduction of patents in developing countries has not been followed by greater investment. Particularly for diseases that primarily affect the poorest countries, our results suggest that alternative mechanisms for inducing R & D may be more appropriate than patents
Strategic responses to parallel trade by Margaret K Kyle( Computer File )
5 editions published in 2007 in English and held by 45 libraries worldwide
"This paper examines how pharmaceutical firms have responded to changes in intellectual property rights and trade barriers that legalized "parallel imports" within the European Union. The threat of arbitrage by parallel traders reduces the ability of firms to price discriminate across countries. Due to regulations on price and antitrust law on rationing supply, pharmaceutical firms may rely on non-price responses. Such responses include differentiation of products across countries and selective "culling" of product lines to reduce arbitrage opportunities, as well as raising arbitrageurs' costs through choice of packaging. Using a dataset of drug prices and sales from 1993-2004 covering 30 countries, I find evidence that the behavior of pharmaceutical firms in the EU with respect to their product portfolios is consistent with attempts to reduce parallel trade. This may at least partially explain why parallel trade has not yet resulted in significant price convergence across EU countries. Accounting for non-price strategic responses may therefore be important in assessing the welfare effects of parallel imports"--National Bureau of Economic Research web site
Inefficiencies in technology transfer : theory and empirics by Marie-Laure Allain( Book )
4 editions published in 2011 in English and held by 9 libraries worldwide
Markets for technology can promote innovation by allowing for division of labor in research and development. Some firms may specialize in the discovery of ideas, while others have a comparative advantage in later stages of development and marketing. However, these gains depend on the timing of technology transfer: the buyer of an idea should take over development at the stage at which he has an efficiency advantage. We show that in an environment with asymmetric information about the value of the idea and where this asymmetry decreases as the product is developed, deviations from the optimal timing of technology transfer will occur. We obtain a condition for the optimal timing to take place and show that the intensity of competition between potential buyers has countervailing effects on this condition. An empirical analysis of licensing contracts signed between biotechnology firms and large pharmaceutical firms confirms our theoretical predictions
Public & private spillovers, location and the productivity of pharmaceutical research by Jeffrey L Furman( Computer File )
3 editions published in 2006 in English and held by 6 libraries worldwide
While there is widespread agreement among economists and management scholars that knowledge spillovers exist and have important economic consequences, researchers know substantially less about the "micro mechanisms" of spillovers -- about the degree to which they are geographically localized, for example, or about the degree to which spillovers from public institutions are qualitatively different from those from privately owned firms (Jaffe, 1986; Krugman, 1991; Jaffe et al., 1993; Porter, 1990). In this paper we make use of the geographic distribution of the research activities of major global pharmaceutical firms to explore the extent to which knowledge spills over from proximate private and public institutions. Our data and empirical approach allow us to make advances on two dimensions. First, by focusing on spillovers in research productivity (as opposed to manufacturing productivity), we build closely on the theoretical literature on spillovers that suggests that knowledge externalities are likely to have the most immediate impact on the production of ideas (Romer, 1986; Aghion & Howitt, 1997). Second, our data allow us to distinguish spillovers from public research from spillovers from private, or competitively funded research, and to more deeply explore the role that institutions and geographic proximity play in driving knowledge spillovers
Parallel trade in pharmaceuticals : firm responses and competition policy by Margaret K Kyle( Article )
2 editions published between 2009 and 2010 in English and held by 4 libraries worldwide
Pharmaceutical industry and competition law : [roundtable] ( Article )
1 edition published in 2010 in English and held by 3 libraries worldwide
Entry and exit innovative industries by Margaret K Kyle( Book )
1 edition published in 2002 in English and held by 1 library worldwide
(Cont.) Firms without complementary assets tend to introduce new products close to the technological frontier. However, their products exit earlier than those of complementary asset firms. These two types of firms appear to pursue different product market strategies, and the mix of both drives the product life cycle. Understanding entry and exit in these settings may provide insights into the diffusion of other new technologies, because pharmaceuticals and laser printers have a number of features in common with other industries of great interest to managers and policymakers at the moment. Thus the insights from this dissertation may be applicable to broad sectors of the economy
Entry and exit in innovative industries by Margaret K Kyle( Book )
1 edition published in 2002 in English and held by 1 library worldwide
Entry in pharmaceutical markets by Margaret K Kyle( Book )
1 edition published in 2002 in English and held by 1 library worldwide
 
Alternative Names
Kelly Kyle, Margaret
Kyle, Margaret
Kyle, Margaret Kelly
Languages
English (42)
Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.